Which has higher valuation & earnings, BCAX or SRRK?

Scholar Rock is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is BCAX or SRRK more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Bicara Therapeutics N/A -35.89% -33.78% Scholar Rock N/A -163.52% -96.67%

Does the media favor BCAX or SRRK?

In the previous week, Scholar Rock had 4 more articles in the media than Bicara Therapeutics. MarketBeat recorded 7 mentions for Scholar Rock and 3 mentions for Bicara Therapeutics. Scholar Rock's average media sentiment score of 1.42 beat Bicara Therapeutics' score of 0.05 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scholar Rock 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, BCAX or APGE?

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A Apogee Therapeutics N/A N/A -$255.84M -$4.33 N/A

Is BCAX or APGE more profitable?

Apogee Therapeutics' return on equity of -32.64% beat Bicara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bicara Therapeutics N/A -35.89% -33.78% Apogee Therapeutics N/A -32.64% -31.25%

Does the media prefer BCAX or APGE?

In the previous week, Apogee Therapeutics had 5 more articles in the media than Bicara Therapeutics. MarketBeat recorded 8 mentions for Apogee Therapeutics and 3 mentions for Bicara Therapeutics. Apogee Therapeutics' average media sentiment score of 0.68 beat Bicara Therapeutics' score of 0.05 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apogee Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BCAX or GRFS?

In the previous week, Bicara Therapeutics and Bicara Therapeutics both had 3 articles in the media. Grifols' average media sentiment score of 1.72 beat Bicara Therapeutics' score of 0.05 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer BCAX or CRSP?

In the previous week, CRISPR Therapeutics had 13 more articles in the media than Bicara Therapeutics. MarketBeat recorded 16 mentions for CRISPR Therapeutics and 3 mentions for Bicara Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.99 beat Bicara Therapeutics' score of 0.05 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BCAX or XENE more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Bicara Therapeutics N/A -35.89% -33.78% Xenon Pharmaceuticals N/A -49.23% -46.42%

Does the media prefer BCAX or XENE?

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Bicara Therapeutics. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 3 mentions for Bicara Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.42 beat Bicara Therapeutics' score of 0.05 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Bicara Therapeutics (BCAX) Competitors

$20.21 -0.35 (-1.72%)

As of 03:29 PM Eastern

Compare

BCAX vs. SRRK, APGE, GRFS, CRSP, and XENE

Should you buy Bicara Therapeutics stock or one of its competitors? MarketBeat compares Bicara Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bicara Therapeutics include Scholar Rock (SRRK), Apogee Therapeutics (APGE), Grifols (GRFS), CRISPR Therapeutics (CRSP), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.

How does Bicara Therapeutics compare to Scholar Rock?

Bicara Therapeutics (NASDAQ:BCAX) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

In the previous week, Scholar Rock had 4 more articles in the media than Bicara Therapeutics. MarketBeat recorded 7 mentions for Scholar Rock and 3 mentions for Bicara Therapeutics. Scholar Rock's average media sentiment score of 1.42 beat Bicara Therapeutics' score of 0.05 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Scholar Rock	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicara Therapeutics currently has a consensus price target of $30.27, indicating a potential upside of 51.24%. Scholar Rock has a consensus price target of $56.00, indicating a potential upside of 25.18%. Given Bicara Therapeutics' higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

Scholar Rock is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

91.1% of Scholar Rock shares are held by institutional investors. 13.8% of Bicara Therapeutics shares are held by company insiders. Comparatively, 13.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bicara Therapeutics' return on equity of -35.89% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Scholar Rock	N/A	-163.52%	-96.67%

Bicara Therapeutics has a beta of -0.53, meaning that its share price is 153% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Summary

Bicara Therapeutics and Scholar Rock tied by winning 7 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to Apogee Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and Apogee Therapeutics (NASDAQ:APGE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

In the previous week, Apogee Therapeutics had 5 more articles in the media than Bicara Therapeutics. MarketBeat recorded 8 mentions for Apogee Therapeutics and 3 mentions for Bicara Therapeutics. Apogee Therapeutics' average media sentiment score of 0.68 beat Bicara Therapeutics' score of 0.05 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apogee Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apogee Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A

Bicara Therapeutics has a beta of -0.53, suggesting that its share price is 153% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

79.0% of Apogee Therapeutics shares are held by institutional investors. 13.8% of Bicara Therapeutics shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Apogee Therapeutics' return on equity of -32.64% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Apogee Therapeutics	N/A	-32.64%	-31.25%

Bicara Therapeutics currently has a consensus target price of $30.27, indicating a potential upside of 51.24%. Apogee Therapeutics has a consensus target price of $114.56, indicating a potential upside of 39.72%. Given Bicara Therapeutics' higher probable upside, equities analysts plainly believe Bicara Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Apogee Therapeutics	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74

Summary

Apogee Therapeutics beats Bicara Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to Grifols?

Bicara Therapeutics (NASDAQ:BCAX) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Bicara Therapeutics presently has a consensus target price of $30.27, suggesting a potential upside of 51.24%. Grifols has a consensus target price of $10.00, suggesting a potential upside of 36.15%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Bicara Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Bicara Therapeutics has a beta of -0.53, suggesting that its stock price is 153% less volatile than the broader market. Comparatively, Grifols has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

Grifols has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Grifols	$7.44B	0.67	$454.82M	$0.19	38.66

Grifols has a net margin of 5.54% compared to Bicara Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Grifols	5.54%	6.21%	2.39%

In the previous week, Bicara Therapeutics and Bicara Therapeutics both had 3 articles in the media. Grifols' average media sentiment score of 1.72 beat Bicara Therapeutics' score of 0.05 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Grifols beats Bicara Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Bicara Therapeutics compare to CRISPR Therapeutics?

Bicara Therapeutics (NASDAQ:BCAX) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Bicara Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
CRISPR Therapeutics	$3.51M	1,364.73	-$581.60M	-$6.22	N/A

69.2% of CRISPR Therapeutics shares are owned by institutional investors. 13.8% of Bicara Therapeutics shares are owned by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bicara Therapeutics has a beta of -0.53, indicating that its share price is 153% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Bicara Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

In the previous week, CRISPR Therapeutics had 13 more articles in the media than Bicara Therapeutics. MarketBeat recorded 16 mentions for CRISPR Therapeutics and 3 mentions for Bicara Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.99 beat Bicara Therapeutics' score of 0.05 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicara Therapeutics currently has a consensus price target of $30.27, indicating a potential upside of 51.24%. CRISPR Therapeutics has a consensus price target of $65.47, indicating a potential upside of 31.82%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Bicara Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53

Summary

Bicara Therapeutics and CRISPR Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to Xenon Pharmaceuticals?

Bicara Therapeutics (NASDAQ:BCAX) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 13.8% of Bicara Therapeutics shares are held by insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bicara Therapeutics has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Xenon Pharmaceuticals	$7.50M	664.86	-$345.91M	-$4.70	N/A

Bicara Therapeutics' return on equity of -35.89% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

In the previous week, Xenon Pharmaceuticals had 3 more articles in the media than Bicara Therapeutics. MarketBeat recorded 6 mentions for Xenon Pharmaceuticals and 3 mentions for Bicara Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.42 beat Bicara Therapeutics' score of 0.05 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bicara Therapeutics currently has a consensus price target of $30.27, suggesting a potential upside of 51.24%. Xenon Pharmaceuticals has a consensus price target of $77.20, suggesting a potential upside of 49.66%. Given Bicara Therapeutics' higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Bicara Therapeutics has a beta of -0.53, suggesting that its share price is 153% less volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Summary

Xenon Pharmaceuticals beats Bicara Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Bicara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAX vs. The Competition

Export

Metric	Bicara Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.32B	$3.30B	$6.44B	$11.74B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-7.20	19.08	24.53	23.69
Price / Sales	N/A	292.12	501.21	105.72
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	2.73	8.05	10.48	6.75
Net Income	-$137.95M	$23.89M	$3.56B	$337.26M
7 Day Performance	0.11%	-3.12%	-1.13%	-1.00%
1 Month Performance	-11.35%	1.50%	1.14%	1.56%
1 Year Performance	59.12%	34.80%	19.72%	23.10%

Bicara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAX Bicara Therapeutics	1.9707 of 5 stars	$20.21 -1.7%	$30.27 +49.8%	+79.1%	$1.32B	N/A	N/A	32
SRRK Scholar Rock	3.3084 of 5 stars	$45.58 +4.1%	$56.00 +22.9%	+33.8%	$5.25B	N/A	N/A	140	Positive News
APGE Apogee Therapeutics	3.221 of 5 stars	$85.00 +2.4%	$114.56 +34.8%	+111.8%	$5.14B	N/A	N/A	91	Analyst Forecast
GRFS Grifols	4.7952 of 5 stars	$7.34 +0.1%	$10.00 +36.2%	-16.9%	$4.99B	$8.51B	38.63	25,247	Positive News
CRSP CRISPR Therapeutics	3.6647 of 5 stars	$51.48 -0.2%	$65.47 +27.2%	+22.3%	$4.98B	$3.51M	N/A	460

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAX) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicara Therapeutics (BCAX) Competitors

BCAX vs. SRRK, APGE, GRFS, CRSP, and XENE

How does Bicara Therapeutics compare to Scholar Rock?

Summary

How does Bicara Therapeutics compare to Apogee Therapeutics?

Summary

How does Bicara Therapeutics compare to Grifols?

Summary

How does Bicara Therapeutics compare to CRISPR Therapeutics?

Summary

How does Bicara Therapeutics compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicara Therapeutics (BCAX) Competitors

BCAX vs. SRRK, APGE, GRFS, CRSP, and XENE

How does Bicara Therapeutics compare to Scholar Rock?

Does the media favor BCAX or SRRK?

Do analysts prefer BCAX or SRRK?

Which has higher valuation & earnings, BCAX or SRRK?

Do institutionals and insiders believe in BCAX or SRRK?

Is BCAX or SRRK more profitable?

Which has more risk and volatility, BCAX or SRRK?

Summary

How does Bicara Therapeutics compare to Apogee Therapeutics?

Does the media prefer BCAX or APGE?

Which has preferable valuation & earnings, BCAX or APGE?

Which has more risk and volatility, BCAX or APGE?

Do insiders and institutionals have more ownership in BCAX or APGE?

Is BCAX or APGE more profitable?

Do analysts rate BCAX or APGE?

Summary

How does Bicara Therapeutics compare to Grifols?

Do analysts recommend BCAX or GRFS?

Which has more risk & volatility, BCAX or GRFS?

Which has better earnings & valuation, BCAX or GRFS?

Is BCAX or GRFS more profitable?

Does the media favor BCAX or GRFS?

Summary

How does Bicara Therapeutics compare to CRISPR Therapeutics?

Which has stronger earnings & valuation, BCAX or CRSP?

Do institutionals & insiders believe in BCAX or CRSP?

Which has more volatility and risk, BCAX or CRSP?

Is BCAX or CRSP more profitable?

Does the media prefer BCAX or CRSP?

Do analysts recommend BCAX or CRSP?

Summary

How does Bicara Therapeutics compare to Xenon Pharmaceuticals?

Do insiders and institutionals have more ownership in BCAX or XENE?

Which has better valuation & earnings, BCAX or XENE?

Is BCAX or XENE more profitable?

Does the media prefer BCAX or XENE?

Do analysts prefer BCAX or XENE?

Which has more volatility and risk, BCAX or XENE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools